Publications by authors named "C Serrate"
Castration-resistant metastatic prostate cancer remains lethal and a therapeutic challenge. Current strategies are geared towards the personalization of treatments based on the identification of relevant molecular targets, including genomic alterations involved in tumoral processes. Among these novel targeted therapies, poly-ADP-ribose polymerase inhibitors (PARPi), by blocking the action of enzymes involved in deoxyribonucleic acid (DNA) repair, induce the destruction of cells carrying defects in homologous recombination repair, often associated with alterations in genes involved in this mechanism.
View Article and Find Full Text PDFTHE ONCOLOGIST, DEATH AND THE PHARMAKON. Stopping chemotherapy for patients treated in oncology is a difficult moment, feared by oncologists because it is often associated with abandonment or even failure in front of a resistant or aggressive disease. End-of-life chemotherapy is still common in oncology departments.
View Article and Find Full Text PDFArticle Synopsis
- Cisplatin-based combination chemotherapy is the standard treatment for muscle-invasive bladder cancer before surgery, but the best chemotherapy options are still unclear.
- In the VESPER trial, patients were given either gemcitabine and cisplatin (GC) or a more intense regimen called dd-MVAC, and their kidney function was monitored during treatment.
- Results showed that at least 4 cycles of cisplatin are necessary for effective treatment, and while extending beyond 4 cycles does not worsen kidney function, it also does not provide significant additional benefits in local cancer control.
Unlabelled: This study looked at whether epidermal growth factor receptor inhibition by the monoclonal antibody panitumumab could increase the efficacy of standard chemotherapy in advanced urothelial cancer. Results were disappointing, with higher toxicity and no improvement in efficacy in the combination arm.
Background: Epidermal growth factor receptor (EGFR) overexpression is frequent and associated with poor outcome in urothelial carcinoma.
Administration of cytotoxic chemotherapy for patients with metastatic cancer and poor performance status is a daily clinical challenge. Guidelines only help to select a therapeutic regimen but do not offer a clear response whether or not the patients should be treated. We performed a prospective analysis in 139 metastatic patients with performance status > 1 according to the Eastern Cooperative Oncology Group scale.
View Article and Find Full Text PDF